Quick Answer
Senti Biosciences Holdings, Inc. reported Cash and Equivalents of $16.42 million for fiscal year 2025.
Senti Biosciences Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $16.42M | -66.0% |
| 2024 | $48.28M | +34.4% |
| 2023 | $35.93M | -37.7% |
| 2022 | $57.62M | +2.8% |
| 2021 | $56.03M | — |
| 2021 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.24M | +16.8% | -43.3% |
| June 30, 2025 | $21.58M | +36.0% | -36.2% |
| March 31, 2025 | $33.80M | +42.5% | -30.0% |
| December 31, 2024 | $48.28M | +34.4% | +360.7% |
| September 30, 2024 | $10.48M | -73.4% | -33.9% |
| June 30, 2024 | $15.86M | -56.8% | -33.1% |
| March 31, 2024 | $23.72M | -24.9% | -34.0% |
| December 31, 2023 | $35.93M | -37.7% | -8.9% |
- Senti Biosciences Holdings, Inc. showed a decrease of -66.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Senti Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: